Skip to search formSkip to main contentSkip to account menu

Nelipepimut-S Plus GM-CSF Vaccine

Known as: NeuVax Plus GM-CSF, Nelipepimut-S Plus Sargramostim, HLA A2/A3-Restricted HER-2/neu Peptide Vaccine Plus GM-CSF 
A cancer peptide vaccine comprised of a human leukocyte antigen (HLA) A2/A3 restricted HER2/neu (ERBB2) peptide from the extracellular domain of the… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
Abstract Vaccine therapies for treatment and prevention of cancer have seen modest degrees of efficacy with wide variation… 
Highly Cited
2019
Highly Cited
2019
Purpose: In phase I/II studies, nelipepimut-S (NP-S) plus GM-CSF vaccine was well tolerated and effectively raised HER2-specific… 
2016
2016
E75 (nelipepimut-S) is an immunogenic peptide derived from the HER2 protein. When combined with the immunoadjuvant granulocyte… 
2016
2016
Purpose: E75, a peptide derived from the Her2/neu protein, is the most clinically advanced vaccine approach against breast cancer… 
2016
2016
1001Background: The role of capecitabine (X) in the adjuvant treatment of BC is not established, and few long-term survival data… 
2015
2015
Background: In an adjuvant phase II trial, the HER2-derived nelipepimut-S (E75) + GM-CSF vaccine (Neuvax) has been shown to… 
Highly Cited
2014
Highly Cited
2014
BACKGROUND E75 (nelipepimut-S) is a human leukocyte antigen (HLA)-A2/A3-restricted immunogenic peptide derived from the HER2… 
Review
2014
Review
2014
Nelipepimut-S (formerly known as E75) is an immunogenic peptide from the HER2 protein that is highly expressed in breast cancer…